REGENXBIO (RGNX) Set to Release Quarterly Earnings on Thursday

REGENXBIO (NASDAQ:RGNX) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.2873) per share and revenue of $10.89 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.35. The firm had revenue of $108.02 million during the quarter, compared to analysts’ expectations of $97.63 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. On average, analysts expect REGENXBIO to post ($3.70) EPS for the current fiscal year and ($2.94) EPS for the next fiscal year.

REGENXBIO Stock Down 0.6%

RGNX stock opened at $7.16 on Tuesday. The firm has a 50 day moving average of $7.91 and a two-hundred day moving average of $9.19. REGENXBIO has a 12 month low of $5.45 and a 12 month high of $16.19. The company has a market capitalization of $472.63 million, a price-to-earnings ratio of -1.89 and a beta of 1.13.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Mizuho initiated coverage on shares of REGENXBIO in a research note on Monday, October 5th. They issued an “outperform” rating and a $22.00 price objective for the company. Morgan Stanley reissued an “overweight” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Friday, August 7th. Robert W. Baird cut their target price on REGENXBIO from $32.00 to $29.00 and set an “outperform” rating on the stock in a report on Tuesday, August 25th. Zacks Research upgraded REGENXBIO from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Barclays cut REGENXBIO from an “overweight” rating to a “hold” rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.17.

REGENXBIO Company Profile

REGENXBIO Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company’s programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.

REGENXBIO’s technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases.